Progress and introduction
of main products
LQ036 is an inhaled VHH antibody drug independently developed by Novamab, targeting IL-4Rα for the treatment of moderate to severe asthma. Compared with existing injectable monoclonal antibodies targeting the same receptor, LQ036 demonstrates significant advantages across multiple key dimensions. LQ036 is expected to become the world’s first nebulized VHH antibody therapy for asthma, breaking conventional treatment paradigms and benefiting a broader range of patients with related indications.
Enhanced Functional Activity:Designed based on a VHH antibody structure, LQ036 exhibits excellent target-binding efficiency and inhibitory potency.
Pulmonary Targeted Delivery:Administered directly to the lungs via a portable nebulizer, LQ036 ensures rapid onset of action, avoids hepatic first-pass metabolism, and reduces the risk of systemic toxicity.
Efficient and Scalable Manufacturing System:Utilizing the Pichia pastoris expression system, LQ036 benefits from low production costs, ease of scale-up, and a mature manufacturing process, providing a solid foundation for future large-scale commercialization.
Robust Safety Profile:LQ036 has completed Phase Ia clinical trials in Australia and Phase I and IIa trials in China, demonstrating favorable safety, tolerability, and low immunogenicity. A 26-week repeated-dose toxicity study in animals showed no relevant toxicities even at high doses, offering strong support for subsequent registration trials.
Clear Efficacy Signals:The Phase IIa POC study in China demonstrated a rapid, significant, and sustained anti-inflammatory effect in the lungs. FeNO levels dropped significantly by Day 2, with a 40% reduction by Day 14 (p=0.007), and gradually returned to baseline after discontinuation. Improvements in lung function and symptoms showed a positive trend, and the favorable safety profile supports advancement to Phase IIb clinical studies.
LQ036 effectively inhibits the binding of IL-4Rα with IL-4 and IL-13, thereby blocking the IL-4/IL-13–IL-4R–mediated signaling pathways. This modulation of immune function includes suppressing Th2 cell differentiation, alleviating airway hypersensitivity reactions, and reducing IgE synthesis. As a result, LQ036 offers therapeutic potential for relieving diseases such as asthma and atopic dermatitis
Moderate and severe asthma、COPD
Nebulized Inhalation
